P579: A PHASE 4 STUDY OF FRACTIONATED GEMTUZUMAB OZOGAMICIN ON QT INTERVAL AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY CD33-POSITIVE ACUTE MYELOID LEUKEMIA

• P. Montesinos,
• V. Kota,
• J. Brandwein,
• P. Bousset,
• R. J. Benner,
• E. Vandendries,
• M. F. McMullin

Affiliations

P. Montesinos

1 Department of Hematology, Hospital Universitario i Politècnico la Fe, Valencia, Spain

V. Kota

2 Department of Medicine: Hematology and Oncology, Medical College of Georgia, Augusta University, Augusta, United States of America

J. Brandwein

3 Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada

P. Bousset

4 Pfizer Inc., Paris, France

R. J. Benner

5 Pfizer Inc., Groton

E. Vandendries

6 Pfizer Inc., Cambridge, United States of America

M. F. McMullin

7 School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast, United Kingdom